Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22871206 | 0.87 | UHRF1 (0.41) | UHRF1HCAR2CYP1A2CYP2A6 | |
| SCHEMBL24936534 | 0.82 | AAK1 (0.33) | HCAR2 | |
| SCHEMBL23082855 | 0.77 | CRHR1 (0.38) | — | |
| SCHEMBL10222485 | 0.76 | UHRF1 (0.43) | UHRF1CYP1A2CYP2A6CA2 | |
| SCHEMBL10528142 | 0.75 | NPC1 (0.34) | — | |
| SCHEMBL24936531 | 0.73 | AAK1 (0.32) | — | |
| SCHEMBL22679386 | 0.72 | UHRF1 (0.40) | UHRF1CYP1A2CYP2A6 | |
| SCHEMBL21711177 | 0.72 | NOS3 (0.38) | — | |
| SCHEMBL21725470 | 0.71 | UHRF1 (0.43) | UHRF1CYP1A2CYP2A6 | |
| SCHEMBL22299472 | 0.70 | CNR2 (0.32) | UHRF1CYP1A2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200048267-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048267-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | UHRF1 876/4885HCAR2 4444/4885CYP1A2 4439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.